General InformationUnity Biotechnology is a senolytic drug developer based in San Francisco, California, founded in 2011 with approximately 100-150 employees focused on eliminating senescent cells to treat age-related diseases.
Funding & FinancialsThe company has raised over $300 million across multiple rounds, with Series C funding led by major healthcare investors and strategic backing from pharmaceutical partners interested in aging-biology therapeutics.
Leadership & TeamKeith Leonard served as CEO, with a team of experienced biotech executives and scientists specializing in cell biology, gerontology, and drug development for age-related conditions.
Recent ActivityRecent developments include advancement of their lead ophthalmologic program UBX1325 through clinical trials and continued expansion of their senolytic pipeline to address multiple age-related indications including fibrosis and neurodegeneration.